325 related articles for article (PubMed ID: 32380083)
1. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
Su K; Li Z; Yu Y; Zhang X
Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
3. Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
Sanghani NS; Haase VH
Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
[TBL] [Abstract][Full Text] [Related]
5. Roxadustat: First Global Approval.
Dhillon S
Drugs; 2019 Apr; 79(5):563-572. PubMed ID: 30805897
[TBL] [Abstract][Full Text] [Related]
6. The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1
Jatho A; Zieseniss A; Brechtel-Curth K; Guo J; Böker KO; Salinas G; Wenger RH; Katschinski DM
Cells; 2022 Feb; 11(4):. PubMed ID: 35203399
[TBL] [Abstract][Full Text] [Related]
7. Effects of Roxadustat on Erythropoietin Production in the Rat Body.
Yasuoka Y; Izumi Y; Fukuyama T; Omiya H; Pham TD; Inoue H; Oshima T; Yamazaki T; Uematsu T; Kobayashi N; Shimada Y; Nagaba Y; Yamashita T; Mukoyama M; Sato Y; Wall SM; Sands JM; Takahashi N; Kawahara K; Nonoguchi H
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164384
[TBL] [Abstract][Full Text] [Related]
8. Stabilizing HIF to Ameliorate Anemia.
Voit RA; Sankaran VG
Cell; 2020 Jan; 180(1):6. PubMed ID: 31951520
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
Liu J; Li S; Yang F; Li T; Li R; Waheed Y; Meng C; Li S; Liu K; Tong Y; Xu H; Tian C; Zhou X
Korean J Intern Med; 2024 May; 39(3):488-500. PubMed ID: 38649158
[TBL] [Abstract][Full Text] [Related]
10. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
Haase VH
Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
[TBL] [Abstract][Full Text] [Related]
11. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
[TBL] [Abstract][Full Text] [Related]
12. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
13. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
[TBL] [Abstract][Full Text] [Related]
14. Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
Nishide S; Uchida J; Matsunaga S; Tokudome K; Yamaguchi T; Kabei K; Moriya T; Miura K; Nakatani T; Tomita S
J Pharmacol Sci; 2020 Jun; 143(2):122-126. PubMed ID: 32199747
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Gupta N; Wish JB
Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety analysis of hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in low-risk myelodysplastic syndromes patients].
Lyu Y; Lin ZH; Yang L; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):290-293. PubMed ID: 38716602
[TBL] [Abstract][Full Text] [Related]
17. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
[TBL] [Abstract][Full Text] [Related]
18. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Chang WT; Lo YC; Gao ZH; Wu SN
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
Packer M
Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]